Moskowitz Craig
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S9-12. doi: 10.1007/s00280-002-0446-2. Epub 2002 Apr 12.
At Memorial Sloan Kettering Cancer Center, New York, we have treated over 400 patients with ICE chemotherapy after failure of upfront anthracycline-based therapy with a response rate of 72% in aggressive non-Hodgkin's lymphoma (NHL) and 84% in Hodgkin's disease. Utilizing this database, we have identified pretreatment prognostic markers capable of predicting the quality of response (complete response vs partial response vs failure) to second-line cytoreductive ICE chemotherapy and consequently autologous stem cell transplantation. We have shown that in aggressive NHL, patients achieving a complete response have superior survival when compared to those achieving only a partial response. By identifying a priori those patients destined to have only a partial response to ICE, we will be able to target a group of chemosensitive patients who are most likely to benefit from improved treatment. Novel treatment strategies designed to increase their complete response rate would be anticipated to improve their long-term survival.
在纽约纪念斯隆凯特琳癌症中心，我们对400多名在一线蒽环类药物为基础的治疗失败后接受ICE化疗的患者进行了治疗，侵袭性非霍奇金淋巴瘤（NHL）的缓解率为72%，霍奇金病的缓解率为84%。利用该数据库，我们确定了能够预测二线减瘤ICE化疗以及自体干细胞移植反应质量（完全缓解与部分缓解与失败）的预处理预后标志物。我们已经表明，在侵袭性NHL中，与仅达到部分缓解的患者相比，实现完全缓解的患者生存期更长。通过预先确定那些注定对ICE仅产生部分反应的患者，我们将能够针对一组最有可能从改进治疗中获益的化疗敏感患者。预计旨在提高其完全缓解率的新型治疗策略将改善他们的长期生存。
